Regenxbio Inc RGNX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/14/21 EDT
36.14UNCH (UNCH)
Volume
45,397
Close
36.14quote price arrow up+0.85 (+2.41%)
Volume
293,602
52 week range
25.93 - 50.26

...

Loading . . .
  • Open35.81
  • Day High36.77
  • Day Low35.15
  • Prev Close35.29
  • 52 Week High50.26
  • 52 Week High Date01/14/21
  • 52 Week Low25.93
  • 52 Week Low Date09/23/20

Key Stats

  • Market Cap1.536B
  • Shares Out42.51M
  • 10 Day Average Volume0.43M
  • Dividend-
  • Dividend Yield-
  • Beta1.19
  • YTD % Change-20.33

KEY STATS

  • Open35.81
  • Day High36.77
  • Day Low35.15
  • Prev Close35.29
  • 52 Week High50.26
  • 52 Week High Date01/14/21
  • 52 Week Low25.93
  • 52 Week Low Date09/23/20
  • Market Cap1.536B
  • Shares Out42.51M
  • 10 Day Average Volume0.43M
  • Dividend-
  • Dividend Yield-
  • Beta1.19
  • YTD % Change-20.33

RATIOS/PROFITABILITY

  • EPS (TTM)-3.11
  • P/E (TTM)-11.60
  • Fwd P/E (NTM)-7.48
  • EBITDA (MRQ)-117.233M
  • ROE (MRQ)-24.90%
  • Revenue (MRQ)155.81M
  • Gross Margin (MRQ)76.15%
  • Net Margin (MRQ)-77.89%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Regenxbio Inc

There is no recent news for this security.

Profile

MORE
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet...
Allan Fox J.D.
Chairman
Kenneth Mills
President
Vittal Vasista
Chief Financial Officer
Address
9600 Blackwell Rd Ste 210
Rockville, MD
20850-3655
United States

Top Peers

SYMBOLLASTCHG%CHG
TBIO
Translate Bio Inc
17.16+0.81+4.95%
SGMO
Sangamo Therapeutics Inc
10.85+0.45+4.33%
IMGN
ImmunoGen Inc
6.75+0.35+5.47%
HRTX
Heron Therapeutics Inc
13.85-1.68-10.85%
FGEN
FibroGen Inc
21.56+0.52+2.47%